UK drug regulatory approves COVID antiviral drug Molnupiravir

The risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease. MHRA recommended the use of Molnupiravir as soon as possible following a positive COVID-19 test and within five days of symptoms onset.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news